Combined mexiletine and flecainide for severe long QT syndrome type 3
- 1 January 2023
- journal article
- editorial
- Published by Wiley in Pediatrics International
- Vol. 65 (1) , e15517
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Sodium channel blockers in the management of long QT syndrome types 3 and 2: A system review and meta‐analysisJournal of Cardiovascular Electrophysiology, 2021
- Letter by Murakami et al Regarding Article, "Systemic Right Ventricle in Adults with Congenital Heart Disease: Anatomic and Phenotypic Spectrum and Current Approach to Management"Circulation, 2018
- Long-term flecainide therapy in type 3 long QT syndromeEP Europace, 2017
- Safety and Efficacy of Flecainide in Subjects with Long QT‐3 Syndrome (ΔKPQ Mutation): A Randomized, Double‐Blind, Placebo‐Controlled Clinical TrialAnnals of Noninvasive Electrocardiology, 2005
- Effects of Flecainide in Patients With New SCN5A MutationCirculation, 2000